115 related articles for article (PubMed ID: 38652147)
1. Long-term outcomes of intraoperative chemotherapy with 5-FU for colorectal cancer patients receiving curative resection (IOCCRC): a randomized, multicenter, prospective, phase III trial.
Zhang RX; Wu XJ; Wan DS; Lin JZ; Ding PR; Liao LE; Lei J; Lu ZH; Li LR; Chen G; Kong LH; Wang FL; Zhang J; Fan WH; Jiang W; Zhou WH; Li C; Li Y; Li XY; Peng JH; Pan ZZ
Int J Surg; 2024 Apr; ():. PubMed ID: 38652147
[TBL] [Abstract][Full Text] [Related]
2. Safety of intraoperative chemotherapy with 5-FU for colorectal cancer patients receiving curative resection: a randomized, multicenter, prospective, phase III IOCCRC trial (IOCCRC).
Zhang RX; Lin JZ; Lei J; Chen G; Li LR; Lu ZH; Ding PR; Huang JQ; Kong LH; Wang FL; Li C; Jiang W; Ke CF; Zhou WH; Fan WH; Liu Q; Wan DS; Wu XJ; Pan ZZ
J Cancer Res Clin Oncol; 2017 Dec; 143(12):2581-2593. PubMed ID: 28849265
[TBL] [Abstract][Full Text] [Related]
3. A commentary on "Long-term outcomes of intraoperative chemotherapy with 5-FU for colorectal cancer patients receiving curative resection (IOCCRC): A randomized, multicenter, prospective, phase III trial".
Ying Z; Zhang G
Int J Surg; 2024 May; ():. PubMed ID: 38814288
[No Abstract] [Full Text] [Related]
4. Prognostic impact of additive chemotherapy after curative resection of metachronous colorectal liver metastasis: a single-centre retrospective study.
Kelm M; Schollbach J; Anger F; Wiegering A; Klein I; Germer CT; Schlegel N; Kunzmann V; Löb S
BMC Cancer; 2021 May; 21(1):490. PubMed ID: 33941104
[TBL] [Abstract][Full Text] [Related]
5. A randomised controlled trial to assess the cost-effectiveness of intensive versus no scheduled follow-up in patients who have undergone resection for colorectal cancer with curative intent.
Mant D; Gray A; Pugh S; Campbell H; George S; Fuller A; Shinkins B; Corkhill A; Mellor J; Dixon E; Little L; Perera-Salazar R; Primrose J
Health Technol Assess; 2017 May; 21(32):1-86. PubMed ID: 28641703
[TBL] [Abstract][Full Text] [Related]
6. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial.
Quénet F; Elias D; Roca L; Goéré D; Ghouti L; Pocard M; Facy O; Arvieux C; Lorimier G; Pezet D; Marchal F; Loi V; Meeus P; Juzyna B; de Forges H; Paineau J; Glehen O;
Lancet Oncol; 2021 Feb; 22(2):256-266. PubMed ID: 33476595
[TBL] [Abstract][Full Text] [Related]
7. Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.
Schmoll HJ; Tabernero J; Maroun J; de Braud F; Price T; Van Cutsem E; Hill M; Hoersch S; Rittweger K; Haller DG
J Clin Oncol; 2015 Nov; 33(32):3733-40. PubMed ID: 26324362
[TBL] [Abstract][Full Text] [Related]
8. Preoperative Hepatic and Regional Arterial Chemotherapy in Patients Who Underwent Curative Colorectal Cancer Resection: A Prospective, Multi-center, Randomized Controlled Trial.
Zhu D; Xia J; Gu Y; Lin J; Ding K; Zhou B; Liang F; Liu T; Qin C; Wei Y; Ren L; Zhong Y; Wang J; Yan Z; Cheng J; Chen J; Chang W; Zhan S; Ding Y; Huo H; Liu F; Sun J; Qin X; Xu J
Ann Surg; 2021 Jun; 273(6):1066-1075. PubMed ID: 33214446
[TBL] [Abstract][Full Text] [Related]
9. Preoperative Serum Carcinoembryonic Antigen Level as a Prognostic Factor for Recurrence and Survival After Curative Resection Followed by Adjuvant Chemotherapy in Stage III Colon Cancer.
Kim CG; Ahn JB; Jung M; Beom SH; Heo SJ; Kim JH; Kim YJ; Kim NK; Min BS; Koom WS; Kim H; Roh YH; Ma BG; Shin SJ
Ann Surg Oncol; 2017 Jan; 24(1):227-235. PubMed ID: 27699609
[TBL] [Abstract][Full Text] [Related]
10. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial.
Bridgewater JA; Pugh SA; Maishman T; Eminton Z; Mellor J; Whitehead A; Stanton L; Radford M; Corkhill A; Griffiths GO; Falk S; Valle JW; O'Reilly D; Siriwardena AK; Hornbuckle J; Rees M; Iveson TJ; Hickish T; Garden OJ; Cunningham D; Maughan TS; Primrose JN;
Lancet Oncol; 2020 Mar; 21(3):398-411. PubMed ID: 32014119
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Role of BRAF Mutation in Stage II/III Colorectal Cancer Receiving Curative Resection and Adjuvant Chemotherapy: A Meta-Analysis Based on Randomized Clinical Trials.
Zhu L; Dong C; Cao Y; Fang X; Zhong C; Li D; Yuan Y
PLoS One; 2016; 11(5):e0154795. PubMed ID: 27138801
[TBL] [Abstract][Full Text] [Related]
12. Aspects of survival from colorectal cancer in Denmark.
Iversen LH
Dan Med J; 2012 Apr; 59(4):B4428. PubMed ID: 22459726
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial.
Klaver CEL; Wisselink DD; Punt CJA; Snaebjornsson P; Crezee J; Aalbers AGJ; Brandt A; Bremers AJA; Burger JWA; Fabry HFJ; Ferenschild F; Festen S; van Grevenstein WMU; Hemmer PHJ; de Hingh IHJT; Kok NFM; Musters GD; Schoonderwoerd L; Tuynman JB; van de Ven AWH; van Westreenen HL; Wiezer MJ; Zimmerman DDE; van Zweeden AA; Dijkgraaf MGW; Tanis PJ;
Lancet Gastroenterol Hepatol; 2019 Oct; 4(10):761-770. PubMed ID: 31371228
[TBL] [Abstract][Full Text] [Related]
14. Prognostic and predictive value of the macroscopic growth pattern in patients undergoing curative resection of colorectal cancer: a single-institution retrospective cohort study of 4,080 Chinese patients.
Li X; Zhao Q; An B; Qi J; Wang W; Zhang D; Li Z; Qin C
Cancer Manag Res; 2018; 10():1875-1887. PubMed ID: 30013394
[TBL] [Abstract][Full Text] [Related]
15. Five-Year Survival Outcomes of Hybrid Minimally Invasive Esophagectomy in Esophageal Cancer: Results of the MIRO Randomized Clinical Trial.
Nuytens F; Dabakuyo-Yonli TS; Meunier B; Gagnière J; Collet D; D'Journo XB; Brigand C; Perniceni T; Carrère N; Mabrut JY; Msika S; Peschaud F; Prudhomme M; Markar SR; Piessen G;
JAMA Surg; 2021 Apr; 156(4):323-332. PubMed ID: 33595631
[TBL] [Abstract][Full Text] [Related]
16. [Prognostic analysis of colorectal liver metastases treated by surgery combined with intraoperative radiofrequency ablation].
Mao R; Zhao JJ; Bi XY; Zhao H; Li ZY; Huang Z; Zhang YF; Chen X; Hu HJ; Wu XL; Hu XH; Cai JQ
Zhonghua Wai Ke Za Zhi; 2017 Jul; 55(7):521-527. PubMed ID: 28655081
[No Abstract] [Full Text] [Related]
17. Metastatic Colorectal Cancer Treated with Combined Liver Resection, Cytoreductive Surgery, and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Predictive Factors for Early Recurrence.
Grange R; Rousset P; Williet N; Guesnon M; Milot L; Passot G; Phelip JM; Le Roy B; Glehen O; Kepenekian V
Ann Surg Oncol; 2024 Apr; 31(4):2378-2390. PubMed ID: 38170409
[TBL] [Abstract][Full Text] [Related]
18. Five-year results of a randomized controlled trial of adjuvant chemotherapy for curatively resected colorectal carcinoma. The Colorectal Cancer Chemotherapy Study Group of Japan.
Jpn J Clin Oncol; 1995 Jun; 25(3):91-103. PubMed ID: 7596054
[TBL] [Abstract][Full Text] [Related]
19. Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial - PACHA-01 (NCT02494973).
Goéré D; Pignon JP; Gelli M; Elias D; Benhaim L; Deschamps F; Caramella C; Boige V; Ducreux M; de Baere T; Malka D
BMC Cancer; 2018 Aug; 18(1):787. PubMed ID: 30081865
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab: A Post Hoc Analysis of the PETACC-8 Trial.
Taieb J; Zaanan A; Le Malicot K; Julié C; Blons H; Mineur L; Bennouna J; Tabernero J; Mini E; Folprecht G; Van Laethem JL; Lepage C; Emile JF; Laurent-Puig P
JAMA Oncol; 2016 May; 2(5):643-653. PubMed ID: 26768652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
